CTLA4 and melanoma: Additionally, in 2022, a non-CAR γδ T cell was developed via the inhibition of CTLA-4 and PD-1 on Vδ2 T cells using monoclonal antibodies to increase γδ T cell infiltration and killing of melanoma cells [201].